Neurotech industry news
Funding rounds, product launches, research findings, and policy updates — published 3× per week.
Synchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
Synchron raises $275M Series D to scale its minimally invasive Stentrode BCI toward broad commercial launch in the US and Australia.
2026-06-15
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.
2026-06-13
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.
2026-06-11
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
Synchron's implantable brain-computer interface has now been placed in 100 patients globally, setting the stage for a pivotal FDA trial later this year.
2026-06-09
Precision Neuroscience Closes $160M Series D to Scale Layer 7 Cortical Interface Platform
Precision Neuroscience raises $160M Series D to expand its minimally invasive brain-computer interface toward broader clinical and commercial deployment.
2026-06-06
Closed-Loop Deep Brain Stimulation Demonstrates Sustained Cognitive Benefits in Landmark Alzheimer's Trial
A 24-month adaptive DBS trial reports significant memory retention improvements in early-stage Alzheimer's patients, reshaping neuromodulation research.
2026-06-04
Synchron Launches Stentrode Home System, Enabling Fully Wireless BCI Use Outside Clinical Settings
Synchron's Stentrode Home System receives FDA clearance, allowing paralyzed patients to use its implanted BCI independently at home.
2026-06-02
FDA Finalizes Guidance Framework for Adaptive Neural Devices, Setting Clearer Path for BCI Approvals
The FDA's finalized guidance on adaptive neural devices establishes new evidentiary standards for BCI approvals, reshaping the regulatory landscape.
2026-05-30
Sponsored content
Reach neurotech decision-makers with your story
Sponsored articles appear in the News feed and the weekly newsletter. $1,500/article.